Drugs or other substances that have a psychoactive effect on the way the brain functions might alter consciousness, emotion, thinking, thoughts, or behaviour. Drugs that have a psychoactive affect on the central nervous system (CNS) change the system's normal function. Drinking, caffeine, nicotine, cannabis, and several analgesics are examples of psychoactive medications and chemicals. In addition, a lot of illicit drugs, including meth, cocaine, heroin, and LSD, are psychoactive chemicals. Substances that are psychotropic are also known as psychoactive drugs. All psychoactive substances have an impact on humans because of how they interact with our natural neurotransmitter systems. The term "psychoactive" is typically associated with illegal or regulated drugs. However, a chemical need not be addictive in order to be deemed psychoactive. When a person needs increasingly higher dosages of psychoactive substances to experience the same effects they formerly did at lesser amounts, this is referred to as tolerance, which is linked to physiological dependency. Tolerance can lead someone to consume more drugs than they should, even to the extent of overdosing and passing away. If this applies to you or anyone you care about, get professional assistance.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States